CD19 and acute lymphoblastic leukemia: For the first time, we report here an analysis of the T-cell-mediated lysis sensitivity of two successive ALL relapses that occurred after three immunotherapies (rituximab, geno-identical allogeneic HSCT, and anti-CD19 CAR T-cells).